A phase II study of Pro-NETU in patients receiving highly emetogenic chemotherapy (HEC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2018
At a glance
- Drugs Fosnetupitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 05 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Sep 2016 Status changed from not yet recruiting to recruiting.
- 25 Aug 2016 New trial record